Payload-Linker

Developing payload‑linker components for next‑generation ADCs demands tight control over potency, safety, and impurity profiles—especially when scaling from gram‑ to kilogram‑level production. This flyer highlights how specialized infrastructure and high‑potency systems enable consistent handling of cytotoxic materials under OEB‑5 conditions. A broad catalog of payloads, linkers, and reactive attachments—ranging from PEGylated constructs and peptide‑modified linkers to auristatins, maytansinoids, camptothecin derivatives, and PBD dimers—supports diverse conjugation strategies while maintaining high purity and reliable supply.

Detailed impurity investigations, chiral‑purity tracking, and established stock of key intermediates streamline route selection and reduce development risk. Dedicated cGMP high‑potency suites, isolator‑based lines, and FDA‑audited plants provide the necessary environment for safe, reproducible scale‑up. Lead times aligned with IND and NDA expectations offer predictability for teams advancing toward clinical milestones.

Organizations pursuing ADC innovation will find valuable insight into managing complexity, ensuring supply continuity, and strengthening the foundation for conjugate‑ready payloads. Access the full flyer to explore the complete technology and service portfolio.